Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director
|
|
IMPAX LABORATORIES INC (IPXL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/07/2018 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 7, 2018 IMPAX LABORATORIES, LLC Delaware 001-34263 65-0403311 30831 Huntwood Avenue, Hayward, CA 94544 240-6000 Registrant's telephone number, including area code Impax Laboratories, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Form of Amended and Restated Certificate of Incorporation of Impax Laboratories, Inc",
"Form of Amended and Restated Bylaws of Impax Laboratories, Inc",
"Limited Liability Company Agreement of Impax Laboratories, LLC",
"Second Supplemental Indenture",
"Term Loan Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and other parties party thereto",
"Revolving Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, the other loan parties from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent and the lenders and other parties party thereto",
"Term Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Revolving Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Termination Agreement, , between Impax Laboratories, LLC (f/k/a Impax Laboratories, Inc.) and Royal Bank of Canada" |
|
| 04/30/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/27/2018 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 03/19/2018 |
8-K
| Other Events |
| 03/07/2018 |
8-K
| Regulation FD Disclosure |
| 03/01/2018 |
8-K
| Investor presentation, Quarterly results |
| 01/24/2018 |
8-K
| Other Events |
| 01/09/2018 |
8-K
| Quarterly results |
| 01/09/2018 |
8-K
| Quarterly results |
| 12/29/2017 |
8-K
| Other Events |
| 12/19/2017 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : December 20, 2017 IMPAX LABORATORIES, INC. Delaware 001-34263 65-0403311 30831 Huntwood Avenue, Hayward, CA 94544 240-6000 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement c...",
"Amendment No. 2 to the Business Combination Agreement",
"Employment Agreement by and among Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and Robert A. Stewart",
"Memorandum of Understanding by and among Amneal Pharmaceuticals LLC, Paul M. Bisaro, Impax Laboratories, Inc. and Atlas Holdings, Inc" |
|
| 12/19/2017 |
8-K/A
| Material Impairments |
| 12/19/2017 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/21/2017 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Amendment No. 1 to the Business Combination Agreement, by and among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation, and Amneal Pharmaceuticals LLC",
"Amendment No. 1 to the Business Combination Agreement, by and among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation, and Amneal Pharmaceuticals LLC" |
|
| 11/09/2017 |
8-K
| Investor presentation, Quarterly results |
| 10/17/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Investor presentation, Quarterly results |
| 05/17/2017 |
8-K
| Form 8-K - Current report |
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 04/05/2017 |
8-K
| Form 8-K - Current report |
| 03/28/2017 |
8-K
| Form 8-K - Current report |
| 03/27/2017 |
8-K
| Form 8-K - Current report |
| 03/01/2017 |
8-K
| Form 8-K - Current report |
| 01/11/2017 |
8-K
| Form 8-K - Current report |
| 12/20/2016 |
8-K
| Form 8-K - Current report |
| 11/28/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 10/19/2016 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of PricewaterhouseCoopers LLP related to the special purpose combined financial statements of Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited",
"Consent of PricewaterhouseCoopers LLP related to the special purpose combined financial statements of Certain Pharmaceutical Products of Allergan plc",
"Audited special purpose combined financial statements of Certain Pharmaceutical Products of Teva Pharmaceuticals Industries Limited, comprised of the special purpose combined statements of assets acquired as of December 31, 2015 and December 31, 2014 and the related special purpose combined statements of revenue and direct expenses for each of the three years in the period ended December 31, 2015, and the related notes, for the Acquired Product Lines",
"Audited special purpose combined financial statements of Certain Pharmaceutical Products of Allergan plc, comprised of the special purpose combined statements of assets acquired as of December 31, 2015 and December 31, 2014 and the related special purpose combined statements of revenue and direct expenses for each of the three years in the period ended December 31, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited special purpose combined interim financial statements of Certain Pharmaceutical Products of Teva Pharmaceuticals Industries Limited, comprised of the special purpose combined statements of assets acquired as of June 30, 2016 and the related special purpose combined statements of revenues and direct expenses for the six month periods ended June 30, 2016 and June 30, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited special purpose combined interim financial statements of Certain Pharmaceutical Products of Allergan plc, comprised of the special purpose combined statements of assets acquired as of June 30, 2016 and the related special purpose combined statements of revenues and direct expenses for the six month periods ended June 30, 2016 and June 30, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited pro forma combined balance sheet as of June 30, 2016 and statements of operations for the year ended December 31, 2015 and the six months ended June 30, 2016, and the related notes, of Impax Laboratories, Inc" |
|
| 08/22/2016 |
8-K
| Appointed a new director |
| 08/09/2016 |
8-K
| Investor presentation, Quarterly results |
| 08/03/2016 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 07/21/2016 |
8-K
| Form 8-K - Current report |
| 06/21/2016 |
8-K
| Form 8-K - Current report |
| 06/02/2016 |
8-K
| Form 8-K - Current report |
|
|
|